Connect with us

Hi, what are you looking for?

Stock

Cardinal Health raises full-year earnings forecast, driven by pharmaceutical segment

Investing.com — Cardinal Health (NYSE:CAH), a major healthcare services and products company, has updated its full-year adjusted earnings per share (EPS) forecast. The company now anticipates its non-GAAP EPS for the fiscal year 2025 to be at the high end of its previously projected range of $7.75 to $7.90. The consensus estimate stands at $7.84.

Shares gained 1% in US pre-market trade.

The revision in the company’s earnings forecast is primarily driven by continued strength within the Pharmaceutical (TADAWUL:2070) and Specialty Solutions segment of the business. The company’s new earnings outlook indicates a positive performance trend in this segment.

In addition to its updated earnings forecast, Cardinal Health announced that it will be presenting at the JPMorgan Annual Healthcare Conference.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

This post appeared first on investing.com






    You May Also Like

    Economy

    A U.N. human rights group confirmed Hamas’ leader in Lebanon, who was recently killed by Israeli strikes, was their employee.  Fateh Sherif was killed...

    Investing

    Astron (ASX:ATR) and Energy Fuels (TSX:EFR,NYSEAMERICAN:UUUU) have completed the establishment of a joint venture to advance the Australia-based Donald rare earths and mineral sands...

    Editor's Pick

    Sen. JD Vance (R-Ohio) and Minnesota Gov. Tim Walz (D) will face off Tuesday night at a CBS News vice-presidential debate in New York....

    Latest News

    A North Korean defector who escaped to the South more than a decade ago was detained after attempting to cross back into North Korea...

    Disclaimer: balanceandcharge.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 balanceandcharge.com